EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients

Réda Chebani, Florian Lombart, Guillaume Chaby, Ali Dadban iD, Sébastien Debarbieux iD, Manuelle-Anne Viguier, Saskia Ingen-Housz-Oro iD, Anne Pham-Ledard, Christophe R Bedane, Catherine Picard-Dahan, Clémence Berthin, Olivier Dereure und 21 weitere

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljad369 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Réda Chebani und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Amiens University Hospital, Amiens, France. Hauptthemen laut MEDLINE: Pemphigoid, Bullous. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: French Study Group on Autoimmune Bullous Diseases, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interest in the use of omalizumab to treat bullous pemphigoid (BP) in the event of resistance or contraindication to conventional therapies is currently based on limited evidence.

Objectives

To assess the effectiveness and safety of omalizumab in BP and to identify predictive factors in response to treatment.

Methods

We conducted a French national multicentre retrospective study including patients with a confirmed diagnosis of BP treated with omalizumab after failure of one or several treatment lines. We excluded patients with clinically atypical BP, as per Vaillant’s criteria. The criteria for clinical response to omalizumab were defined according to the 2012 international consensus conference. Anti-BP180-NC16A IgE enzyme-linked immunosorbent assay was performed on sera collected before initiating omalizumab, when available.

Results

Between 2014 and 2021, 100 patients treated in 18 expert departments were included. Median age at diagnosis was 77 years (range 20–98). Complete remission (CR) was achieved in 77% of patients, and partial remission in an additional 9%. CR was maintained ‘off therapy’ in 11.7%, ‘on minimal therapy’ in 57.1%, and ‘on non-minimal therapy’ in 31.2%. Median time to CR was 3 months (range 2.2–24.5). Relapse rate was 14%, with a median follow-up time of 12 months (range 6–73). Adverse events occurred in four patients. CR was more frequently observed in patients with an increased serum baseline level of anti-BP180-NC16A IgE (75% vs. 41%; P = 0.011). Conversely, urticarial lesions, blood total IgE concentration or eosinophil count were not predictive of CR. Patients with an omalizumab dosage > 300 mg every 4 weeks showed a similar final outcome to those with a dosage ≤ 300 mg every 4 weeks, but control of disease activity [median 10 days (range 5–30) vs. 15 days (range 10–60); P < 0.001] and CR [median 2.4 months (range 2.2–8.2) vs. 3.9 months (range 2.3–24.5); P < 0.001] were achieved significantly faster.

Conclusions

We report the largest series to date of BP treated by omalizumab and confirm its effectiveness and safety in this indication. Serum baseline level of anti-BP180-NC16A IgE may predict response to treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousHumansYoung AdultAdultMiddle AgedAgedAged, 80 and overCollagen Type XVIIOmalizumabRetrospective StudiesNon-Fibrillar CollagensAutoantigensImmunoglobulin EAutoantibodies

Substanzen

Collagen Type XVIIOmalizumabNon-Fibrillar CollagensAutoantigensImmunoglobulin EAutoantibodies

Autor:innen und Institutionen

  • Department of Dermatology, Amiens University Hospital, Amiens, France.
  • Department of Dermatology and Referral Centre for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Hôpitaux Universitaires de Paris Seine-Saint-Denis, AP-HP, Université Sorbonne Paris Nord, Bobigny, France.

ORCID-Profile: Ali Dadban, Sébastien Debarbieux, Saskia Ingen-Housz-Oro, Thomas Gille, Marina Alexandre

Förderung

  • French Study Group on Autoimmune Bullous Diseases
  • NIH

Zitieren

APA

Chebani, R., Lombart, F., Chaby, G., Dadban, A., Debarbieux, S., Viguier, M. A., Ingen-Housz-Oro, S., Pham-Ledard, A., Bedane, C. R., Picard-Dahan, C., Berthin, C., Dereure, O., Konstantinou, M. P., Castel, M., Jouen, F., Joly, P., Seta, V., Duvert-Lehembre, S., Le Roux, C., …, & French Study Group on Autoimmune Bullous Diseases (2024). Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad369

Vancouver

Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguier MA, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad369

BibTeX
@article{Chebani2024,
  author = {Chebani, Réda and Lombart, Florian and Chaby, Guillaume and Dadban, Ali and Debarbieux, Sébastien and Viguier, Manuelle-Anne and Ingen-Housz-Oro, Saskia and Pham-Ledard, Anne and Bedane, Christophe R and Picard-Dahan, Catherine and Berthin, Clémence and Dereure, Olivier and Konstantinou, Maria-Polina and Castel, Marion and Jouen, Fabienne and Joly, Pascal and Seta, Vannina and Duvert-Lehembre, Sophie and Le Roux, Christelle and Quereux, Gaëlle and Sassolas, Bruno and Brenaut, Emilie and Sin, Carole and Richard, Marie-Aleth and Bérard, Frédéric and Giusti, Delphine and Belmondo, Thibaut and Gille, Thomas and Caux, Frédéric and Prost-Squarcioni, Catherine and Grootenboer-Mignot, Sabine and Alexandre, Marina and French Study Group on Autoimmune Bullous Diseases, French Study Group on Autoimmune Bullous Diseases},
  title = {Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljad369}
}
Kostenlos starten →